target to be reinforced in situations where cardioprotection is needed, for example, in acute myocardial infarction, complex cardiovascular surgery, or interventions. 8, 9 There is experimental evidence for both, a neuronal 12 or a humoral 13 transfer, as well for their interaction. 14 Clearly, humoral transfer of a cardioprotective signal from one individual to another is possible, 15 even if the recipient is an isolated heart preparation from a different species. 13, 16 The transfer factor(s) appear(s) to be <15 kDa in size because it is still operative when dialyzed through a membrane with such cutoff. 13 Some studies have identified specific factors, such as stromal cell-derived factor 1 17 , nitrite, 16 micro-RNA-144 18 , in specific models and species, but no unequivocal candidate transfer factor has yet emerged. More systematic studies using proteomic approaches to identify the protective humoral transfer factor in plasma have also failed. [19] [20] [21] Apart from the transfer signal, the recruited cardioprotective signaling pathways within the target myocardium are unclear in detail. To what extent RIPC shares established cardioprotective signaling pathways, such as the reperfusion injury salvage kinase (RISK) pathway 22 or the survival activating factor enhancement (SAFE) pathway, 23 with other conditioning strategies remains still to be clarified. 24, 25 Against this background of a so far largely elusive search for the enigmatic humoral transfer factor of RIPC's protection, we have now taken a novel, retrograde approach to characterize the properties of the upstream humoral transfer factor by the downstream myocardial signal transduction which it may activate. To this effect, we have used our established and clinically relevant pig model 26 and established IS reduction by a RIPC algorithm. To further evaluate the role of humoral transfer of the protective stimulus, we obtained arterial plasma from pigs undergoing RIPC or a placebo (PLA) procedure and tested its cardioprotective properties in an isolated, saline-perfused bioassay rat heart undergoing global ischemia and reperfusion with IS as end point. To test the involvement of the RISK and SAFE pathways, we used both immunoblotting of the respective kinase phosphorylation and a pharmacological antagonist approach using combined phosphatidylinositol(4,5)-bisphosphate-3-kinase inhibition by wortmannin 27 and mitogen-ERK-activator-kinase 1/2 inhibition by U0126 28 for RISK blockade or janus kinase 2 inhibition with AG490 or inhibition of signal transducer and activator of transcription 3 (STAT3) phosphorylation with stattic for SAFE blockade, respectively. 29, 30 In pigs, the antagonists were given before the RIPC maneuver and covered both the potential release of the protective factor and its potential action on the ischemic/ reperfused myocardium. Stattic could not be used in pigs in situ because of its high toxicity. 31 In the isolated rat hearts, the antagonists were given before infusion of plasma from pigs that had undergone RIPC or a PLA procedure and thus only antagonized the action of the cardioprotective signal on the ischemic/reperfused recipient heart.
Methods
The experimental protocols were approved by the Bioethical Committee of the district of Düsseldorf (pigs: G1240/11; rats: B1322/12).
Experiments in Pigs

Experimental Preparation
Göttinger minipigs (weight, 29.9±2.2 kg; age, 15±2 months) were sedated with flunitrazepam (0.4 mg/kg, Rohypnol; Roche, Grenzach-Wyhlen). Anesthesia was induced by etomidate (0.3 mg/ kg, Hypnomidat; Janssen-Cilag, Neuss) and sufentanil (1 µg/kg IV, Sufenta; Janssen-Cilag, Neuss). Anesthesia was maintained by artificial ventilation with isoflurane (2%) in oxygen-enriched air. This anesthesia is identical to that used in our institution for patients undergoing surgical coronary revascularization. 10 The pigs were placed on a heated table and covered with drapes to prevent hypothermia. Esophageal temperature was thus kept at 36.9±0.9°C. One jugular vein was cannulated with a teflon catheter for volume replacement and intravenous drug administration. ECG-lead II was continuously monitored. The left hindlimb was shaved, and a tourniquet was placed around it for later induction of RIPC. After completion of the RIPC or PLA maneuver (see below), respectively, the common carotid arteries were cannulated to measure arterial pressure and to withdraw blood from the descending thoracic aorta as reference for the regional blood flow measurement. After a left lateral thoracotomy, the heart was exposed and instrumented with a micromanometer (P7; Konigsberg Instr., Pasadena, CA) in the left ventricle. A teflon catheter was placed in the left atrium for the injection of colored microspheres. 32 A silk suture was placed around the left anterior descending (LAD) coronary artery distal to its second diagonal branch for later coronary occlusion. Ventricular fibrillation during the protocol was immediately terminated by electric countershock.
Experimental Protocols RIPC (n=15)
RIPC was induced by tightening of the tourniquet around the left hindlimb; pale skin was taken to indicate leg ischemia. The tourniquet was released after 5 minutes, and the hindlimb was reperfused for 5 minutes. Skin blush indicated reperfusion. The ischemia/reperfusion cycle in the leg was repeated 4 times in total, just after induction of anesthesia and establishment of venous access. Then, the surgical preparation was completed. One hour after the RIPC maneuver, 100 to 120 mL arterial blood was withdrawn and sampled in vials containing Lithium-heparin and immediately centrifuged at 4°C with 800g for 10 minutes. Separated plasma was centrifuged at 4°C with 4500g for additional 10 minutes. The separated plasma was stored at −80°C for later use and again centrifuged for 10 minutes at 4500g and filtered (0.2 µm pore size) before use. The sampled blood volume was replaced with saline. In preliminary experiments, we had ascertained that storage of plasma for up to 83 days at −80°C did not attenuate its IS reducing potential. After measurement of systemic hemodynamics and regional myocardial blood flow, myocardial drill biopsies (2-4 mg) were taken from the area at risk. Samples were immediately snap-frozen in liquid nitrogen and stored at −80°C for later Western blot analysis.
Then, the suture around the LAD was carefully tightened against a soft silicone plate for 60 minutes. At 5 minutes ischemia, systemic hemodynamics and regional myocardial blood flow were measured again. Reperfusion was induced by release and quick removal of the suture and confirmed by the disappearance of the light blue color and the reappearance of red color on the surface of the reperfused myocardium. Myocardial biopsies were again sampled at 10 minutes reperfusion, and systemic hemodynamics were measured at 30, 60, and 120 minutes reperfusion. Reperfusion was continued for 3 hours before the experiment was terminated.
Nonstandard Abbreviations and Acronyms
PLA (n=13)
The experimental protocol was identical to that of that for RIPC, except that the RIPC maneuver was omitted.
RIPC With Pharmacological Blockade of the RISK Pathway (RIPC+RISK-BL; n=3)
The experimental protocol was identical to that for RIPC, except that the RIPC maneuver and the subsequent protocol were performed in the presence of blockade of the RISK pathway. RISK blockade was induced 10 minutes before the RIPC maneuver by intravenous injection of the phosphatidylinositol(4,5)-bisphosphate-3-kinase inhibitor wortmannin 27 (300 µg/kg bolus) and the mitogen-ERK-activator-kinase 1/2 inhibitor U0126 28 (3 mg/kg bolus+15 µg/kg per min continuous infusion up to 10 minutes reperfusion).
RIPC With Pharmacological Blockade of the SAFE Pathway (RIPC+SAFE-BL; n=3)
The experimental protocol was identical to that for RIPC, except that the RIPC maneuver and the subsequent protocol were performed in the presence of blockade of the SAFE pathway. SAFE blockade was induced by repetitive intravenous infusion of 10 mg/ kg each of the janus kinase 2 inhibitor AG490 at 10 minutes before the RIPC maneuver, at 10 minutes before LAD occlusion, and at 10 minutes before reperfusion. AG490 was dissolved in 8 mL dimeth-ylsulfoxide+6 mL saline and slowly administered for 10 minutes using a syringe pump. We omitted additional protocols with only ischemia/reperfusion in the presence of RISK or SAFE pathway blockade because we have already shown before that blockade of these pathways per se does not alter IS. 31, 33 
IS in In Situ Pig Hearts
At the end of each experiment, the LAD was reoccluded, and 5 mL blue dye (Patentblau V, Guerbet GmbH, Sulzbach, Germany) was quickly injected into the left atrium to delineate the area at risk as remaining unstained. Infarcted tissue was demarcated by triphenyl tetrazolium chloride staining. The area at risk was calculated as fraction of the left ventricle, and the IS was calculated as fraction of the area at risk.
Experiments in Isolated Rat Hearts
Experimental Preparation
Male Lewis rats (250-400 g) were anesthetized by an intraperitoneal injection of sodium pentobarbital (Narcoren, Merial, Hallbergmoos, Germany). The injection was supplemented with 1000 IU heparin to attenuate coagulation. The heart was rapidly excised and placed in ice-cold saline before it was mounted on a Langendorff apparatus. Modified Krebs-Henseleit buffer (in mmol/L: NaCl, 118.0: KCl, 4.7: MgSO 4 , 1.6: KH 2 PO 4 , 1.2; glucose, 5.6: NaHCO 3 , 24.9; sodium pyruvate, 2.0; CaCl 2 , 2.0; gassed with 95% O 2 and 5% CO 2 in a 37°C prewarmed reservoir) was used for retrograde perfusion at constant pressure (65-68 mm Hg). The perfusate temperature was held constant by a heat exchanger located next to the aortic cannula. A fluid-filled latex balloon was inserted through the left atrium into the left ventricle and connected to a pressure transducer (CODAN pvb Medical, Lensahn, Germany). Minimal left ventricular pressure was set to 5 to 15 mm Hg by balloon inflation, heart rate was set to 400 bpm by atrial pacing, and coronary flow was measured using an inline ultrasonic flow probe (ME2-PXN TransSonic, Maastricht, NL) connected to the aortic cannula. During the entire experiment, the hearts were continuously immersed in 37°C warm buffer to avoid hypothermia. Hearts were allowed to stabilize for 20 minutes before a protocol was started.
Experimental Protocols
Common to all protocols in the isolated bioassay rat hearts is the infusion of plasma which had been taken during the experiments in pigs. The plasma was added via a syringe pump to the perfusate (1:10 volume ratio) before passing the heat exchanger. The plasma dilution and the volume and timing of its infusion into rat hearts had been elaborated and optimized in preliminary experiments. When experiments were performed with specific blockade of either the RISK or the SAFE pathway, the perfusate containing the respective blocker substances was freshly prepared in a second preheated reservoir, and perfusate reservoirs were then switched by a mechanical valve. The efficacy of the respective signaling pathway blockade was estimated by Western blot analysis of myocardial samples taken from the rat heart at the end of each protocol. Sampled tissue was snap-frozen in liquid nitrogen and stored at −80°C.
RIPC Plasma (pRIPC; n=15)
Plasma taken from a pig subjected to a RIPC maneuver was infused for 8 minutes. After brief washout of plasma, global ischemia was induced for 30 minutes by full stop of retrograde perfusion. The plasma infusion was continued during the initial 5 minutes of 120 minutes reperfusion at constant pressure (65-68 mm Hg).
RIPC Plasma+In Vitro Blockade of the RISK Pathway (pRIPC+RISK-BL; n=5)
Wortmannin and U0126 were dissolved in dimethylsulfoxide and added to the perfusate at a final concentration of 1 µmol/L wortmannin and 1 µmol/L U0126 for 20 minutes before plasma infusion. Thereafter, the protocol was identical to that for pRIPC.
RIPC Plasma+In Vitro Blockade of the SAFE Pathway (pRIPC+SAFE-BL; n=4)
Stattic was dissolved in dimethylsulfoxide and added to the perfusate at a final concentration of 10 µmol/L starting at 20 minutes before plasma infusion and continued up to the end of the experiment. The protocol was otherwise identical to that for pRIPC.
PLA Plasma (pPLA; n=13)
The protocol was identical to that for pRIPC, except that plasma taken from a pig subjected to a PLA maneuver was used.
PLA Plasma+In Vitro Blockade of the RISK Pathway (pPLA+RISK-BL; n=5)
The protocol was identical to that for pRIPC with RISK blockade, except that plasma taken from a pig subjected to a PLA maneuver was used.
PLA Plasma+In Vitro Blockade of the SAFE Pathway (pPLA+SAFE-BL; n=4)
The protocol was identical to that for pRIPC with SAFE blockade, except that plasma taken from a pig subjected to a PLA maneuver was used.
Each plasma sample that was subjected to a protocol with either RISK or SAFE blockade was also used in protocols without blockade (pRIPC and pPLA), respectively, so that paired comparisons for the same plasma without and with RISK or SAFE blockade, respectively, were possible.
At the end of each protocol, the apex of the heart (≈50 mg) was cutoff and quickly frozen in liquid nitrogen for later analysis by Western blot. The rest of the heart was frozen in Cryomatrix (Thermo Fisher Scientific, Germany) at −20°C and cut into transverse 1-mm thick slices. Infarcted tissue was demarcated by staining with 2% triphenyl tetrazolium chloride solution containing 5% dextran at 37°C for 20 minutes. Stained slices were weighed and photographed from both sides. The total slice area and the infarcted area were measured by computer-assisted planimetry. After normalization for weight, IS was calculated as fraction of ventricular mass. 
Western Blot Analysis of Myocardial Samples (Pig and Isolated Rat Heart Experiments)
Protein aliquots of 20 µg for pig myocardium or 30 µg for rat myocardium were electrophoretically separated on precasted sodium dodecyl sulphate-polyacrylamide gel electrophoresis gels (BioRad, Munich, Germany) and transferred to polyvinylidene fluoride membranes. After blocking, membranes were incubated with antibodies (Online Table I ) directed against the phosphorylated forms of protein kinase B (AKT), extracellular-signal-regulated kinase 1/2 (ERK1/2), STAT3, and STAT5. After incubation with the respective secondary antibodies, immunoreactive signals were detected by chemiluminescence and quantified with ChemCam/LabImage1D software (INTAS, Göttingen, Germany). Membranes were reprobed for detection of the respective total form of each protein. Immunoreactivities of phosphorylated protein were normalized to those of the respective total form of the protein.
Investigators assessing IS and performing Western blot analyses were blinded to the RIPC versus PLA protocol or the origin of the plasma, respectively.
Statistics
All data are mean±SD. Area at risk and IS were compared by one-way ANOVA. Hemodynamics, transmural blood flow, and the time courses of protein phosphorylation were analyzed by two-way ANOVA for repeated measures (SigmaStat 3.5, Erkrath, Germany). When a significant difference was detected, individual mean values were compared by Fisher least significant difference post hoc tests. Differences were considered significant at the level of P<0.05.
Results
Experiments in Pigs
Three pigs were retrospectively excluded from analysis. In one pig each of the RIPC and the PLA group, ischemia was not severe enough (transmural blood flow, >0.06 mL/min per g). In one pig from the PLA group, the suture for LAD occlusion was not fixed tightly enough such that there was no infarct at all. Nevertheless, the plasma samples taken from these pigs before ischemia were used in the isolated rat heart experiments.
Systemic Hemodynamics in Pigs
Heart rate was not different between groups and remained unchanged throughout the protocol. Left ventricular pressure decreased with the onset of ischemia and remained below preischemic values up to the end of the protocol (Table 1) .
Regional Myocardial Blood Flow, Area at Risk, and IS in Pigs
Transmural blood flow in the area at risk was not different between groups before ischemia and during ischemia ( Table 2) . The area at risk was not different between groups ( Table 2) . RIPC reduced IS when compared with PLA ( Figure 1 ). RIPC protected against infarction also in the presence of in vivo RISK blockade (RIPC+RISK-BL), whereas RIPC's protection was completely abolished in the presence of in vivo SAFE blockade (RIPC+SAFE-BL; Figure 1 ). 
Protein Phosphorylation in Pig Myocardium
The levels of phosphorylated AKT and ERK1/2, normalized to their respective total protein, were higher at 10 minutes reperfusion than before ischemia, but not different between RIPC and PLA. With RIPC+RISK-BL, levels of phosphorylated AKT and ERK1/2 were attenuated, both before ischemia and at 10 minutes reperfusion ( Figure 2 ). The level of phosphorylated STAT3, normalized to total STAT3 protein, was increased at 10 minutes reperfusion versus before ischemia only with RIPC, but not with PLA or RIPC in the presence of SAFE blockade by AG490 ( Figure 2 ). AG490 did not attenuate the increased phosphorylation of AKT and ERK1/2 (Online Figures I and II) . The level of phosphorylated STAT5, normalized to total STAT5 protein, decreased with reperfusion in both groups (Online Figure III) . Membranes and chemiluminescence signals for AKT, ERK1/2, and STAT3 are displayed in Online Figures IV to VI.
Experiments in Isolated Rat Hearts
Coronary Flow and Left Ventricular Developed Pressure in Isolated Rat Hearts
Coronary flow and left ventricular developed pressure were not different between groups at baseline. Infusion of pig plasma slightly decreased developed pressure in all groups. Developed pressure ceased ≈5 minutes after the onset of global ischemia and recovered only partially during reperfusion. Coronary flow at reperfusion was lower than baseline but not different between pRIPC and pPLA. Except for pRIPC+RISK-BL, coronary flow at reperfusion was lower in the presence of RISK and SAFE blockade than in the respective untreated groups (Online Table II ).
IS in Isolated Rat Hearts
IS was decreased with infusion of plasma taken from pigs subjected to RIPC (pRIPC) when compared with infusion of plasma from pigs subjected to PLA (pPLA; Figure 3 ). The average IS with pPLA was similar to that observed after 30 minutes ischemia and 2 hours reperfusion without plasma infusion (Online Figure VII) . The protective effect of pRIPC was abolished when either RISK blockade, that is, pretreatment with wortmannin and U0126, or SAFE blockade, that is, pretreatment with stattic, were induced in the isolated bioassay rat heart before plasma infusion (pRIPC+RISK-BL and pRIPC+SAFE-BL). The RISK or SAFE blockade, respectively, did not affect IS when the isolated rat hearts were treated with plasma taken from pigs subjected to PLA (pPLA+RISK-BL and pPLA+SAFE-BL; Figure 3 ).
IS reduction in the rat heart was also not observed with plasma taken from pigs in which the RIPC maneuver was performed in the presence of RISK or SAFE blockade (Online Figure VII) .
Protein Phosphorylation in Rat Myocardium
In myocardial samples from rat hearts after 120 minutes reperfusion, the levels of phosphorylated AKT and ERK1/2, normalized to their respective total protein, were higher with pRIPC than with pPLA. The increases in AKT and ERK1/2 phosphorylation were abolished when RISK blockade was induced before pRIPC infusion (Figure 4 ). RISK blockade did not affect STAT3 (Online Figure VIII) . The level of phosphorylated STAT3, normalized to total STAT3 protein, was higher with pRI-PC than with pPLA, and this increase was abolished in the presence of SAFE blockade by stattic ( Figure 4 ). SAFE blockade did not affect AKT or ERK1/2 (Online Figure IX) . The level of phosphorylated STAT5, normalized to total STAT protein, was not different between pRIPC and pPLA (Online Figure X) .
Membranes and chemiluminescence signals for AKT, ERK1/2, and STAT3 are displayed in Online Figures XI to XIII.
Discussion
Major Findings
We have taken a novel, retrograde approach to identify the still enigmatic humoral transfer factor of RIPC's protection by characterizing its properties through the downstream myocardial signal transduction which it might activate. Using this approach, we could first demonstrate that the myocardial signal transduction pathways recruited by the humoral transfer factor of remote preconditioning are identical to those recruited by local postconditioning, in both isolated perfused rat hearts and in pigs in situ. Although admittedly we could not identify the ultimate factor, our findings will further narrow down the exhaustive and painful search for such needle in the haystack and facilitate its identification.
Methodological Considerations
In the present study, we confirmed RIPC protection against myocardial infarction in our clinically relevant pig model, 26 in line with the recent CAESAR recommendations for experimental studies on cardioprotection. 34 In our current study, we have used the same anesthetic regime as was used in our studies on RIPC in patients undergoing surgical coronary revascularization. 10 More specifically, we used isoflurane and not propofol because propofol interferes with the cardioprotection by RIPC. 35, 36 Of note in this context, the two studies on RIPC in patients undergoing cardiac surgery under cardiopulmonary bypass (ERICCA and RipHeart), which have recently presented preliminary neutral results at the hot line sessions of the American College of Cardiology and the German Cardiac Society, respectively, have used propofol in the majority of patients. To further elucidate the underlying myocardial signal transduction of RIPC, we have collected pig plasma after completion of the RIPC maneuver or PLA, respectively, and transferred one or more potentially protective blood-borne factor(s) from the in vivo pig model to isolated perfused rat hearts, which were used as an in vitro bioassay. A technical advantage of such bioassay is the abundance of plasma for use in testing different signaling pathways. Plasma taken from pigs after the RIPC maneuver and diluted 1:10 still reduced IS in the isolated bioassay rat heart, whereas diluted plasma taken from pigs after PLA did not. The rationale for taking the plasma with 1 hour delay after the RIPC procedure was again to mimic the time course of our RIPC protocol in patients undergoing cardiac surgery. 10 In preliminary studies, we found no evidence that plasma taken with less delay caused greater protection.
The samples for Western blot analysis were taken from pig and rat hearts, in which IS was also determined by triphenyl tetrazolium chloride staining such that there was evidence for protection or lack of it in each instance. In the pig hearts, the first samples taken before myocardial ischemia reflect not a truly naive baseline but the situation ≈1 hour after the RIPC protocol or PLA, respectively, such that activation of AKT, ERK1/2, or STAT3 at earlier time points after the RIPC stimulus might have been missed. Nevertheless, just before myocardial ischemia, there was no difference in the myocardial expression and phosphorylation status of AKT, ERK1/2, and STAT3 between pigs which had undergone RIPC or PLA. The increased phosphorylation of AKT, ERK1/2, and STAT3 at 10 minutes reperfusion in biopsy samples from pig hearts probably reflects a situation where activated proteins might play a causal role in attenuating reperfusion injury, and we could ascertain such causal role for STAT3 through Western blot analysis combined with a pharmacological antagonist approach. In contrast in the isolated rat hearts, tissue for Western blot analysis was taken only after 2 hours reperfusion when the increased phosphorylation levels probably are no longer representative of earlier time points when protection has occurred. Nevertheless, the Western blot analysis after 2 hours reperfusion still provided evidence that the pharmacological antagonists indeed hit their targets.
Myocardial Signal Transduction of RIPC
The focus of our study was on those myocardial signal transduction cascades that have already been identified in cardioprotection by ischemic preconditioning and postconditioning, 24, 25 that is, AKT and ERK1/2 as central elements of RISK 22 and STAT3 as a central element of SAFE. 31, 37 As in our previous studies on ischemic postconditioning, 31, 33 we assessed the time courses of phosphorylation of AKT, ERK1/2, STAT3, and STAT5 by the RIPC maneuver in sequential biopsies taken from myocardium at risk in pigs. The observed IS reduction by RIPC was not associated with a greater increase in phosphorylation of AKT and ERK1/2 at reperfusion than with PLA. RIPC in the presence of pharmacological RISK blockade was still protective, although the increases in AKT and ERK1/2 phosphorylation at reperfusion were largely attenuated, consistent with our previous study in which RISK activation was not mandatory to confer protection by ischemic postconditioning. 33 Consequently, the activation of the RISK pathway was apparently not causal for cardioprotection by RIPC. In contrast, a recent study in pigs suggested an involvement of AKT in RIPC's cardioprotection 38 ; however, the findings of this particular study are somewhat ambiguous because protection by RIPC was still observed when the phosphorylation of AKT was abrogated by the adenosine antagonist 8-sulfophenyltheophylline.
An obvious increase in the phosphorylation of STAT3 at reperfusion was observed only with RIPC and not with PLA in pigs. The pretreatment of pigs with AG490, a blocker of janus kinase 2, attenuated such increase in STAT3 phosphorylation at reperfusion with RIPC and resulted in a complete loss of RIPC protection, supporting a causal role of STAT3 in RIPC protection. This observation is again consistent with our previous study which has shown a causal role of STAT3 in cardioprotection by ischemic postconditioning in pigs. 31 Plasma taken from pigs after the RIPC maneuver and diluted 1:10 still reduced IS in the isolated bioassay rat heart, whereas diluted plasma taken from pigs after PLA did not. With RIPC plasma, the phosphorylation of AKT and ERK1/2 in the rat myocardium at reperfusion was greater than with PLA plasma. RISK blockade in the isolated bioassay rat heart before infusion of pRIPC abolished the activation of both RISK and IS reduction. Such causal involvement of RISK in cardioprotection in rodent hearts is consistent with many previous studies. 22, 39 The lack of protection with plasma taken from pigs in which the RIPC maneuver was performed in the presence of a RISK blockade is then expected (Online Figure VII) . Plasma taken from pigs subjected to a RIPC maneuver when compared with PLA plasma also increased the phosphorylation of STAT3 in the isolated bioassay rat heart. This observation supports the notion that the SAFE pathway is also involved in cardioprotection in rodent hearts. 40, 41 Consequently, blockade of STAT3 phosphorylation by stattic abolished the protective effect of pRIPC. Plasma taken from pigs in which the RIPC maneuver was performed in the presence of SAFE blockade also did not protect isolated bioassay rat hearts from infarction. However, it cannot be distinguished whether the SAFE pathway blockade in the pig before the RIPC maneuver prevented the release of a protective factor and thus its transfer to the isolated rat heart or whether the residual amounts of AG490 in the pig plasma prevented protection in the rat heart per se.
The signal transduction of cardioprotection is highly species dependent. In small rodents, RISK activation is mandatory to confer protection, 22 but SAFE activation seems to play also an important role. 23, 37 Apparently, there is a close interaction of RISK and SAFE pathways in the rat heart such that either blockade abrogates protection, consistent with previous studies. 42, 43 In contrast, RISK activation is not necessary for cardioprotection in pigs 33 or humans, 44 but an activation of STAT is certainly involved. 31, 44 However, species differences are also evident even within the SAFE signal transduction scheme. Cardioprotection by ischemic postconditioning in pigs requires the activation of STAT3, 31 whereas cardioprotection by RIPC in humans is characterized by an activation of STAT5 and not STAT3. 44 Such species differences in myocardial signal transduction of cardioprotection were also confirmed in our current experiments. Only STAT3 activation was causally involved in cardioprotection by RIPC in the pig, whereas phosphorylation of STAT5 decreased with reperfusion and was not different between RIPC and PLA. In the isolated bioassay rat heart, both the RISK and the SAFE pathways were activated by plasma taken from pigs after a RIPC maneuver. Only STAT3, but not STAT5, was activated in the isolated bioassay rat heart. Obviously, the blood-borne factor(s) present in the plasma of pigs after RIPC was/were able to activate both the RISK and the SAFE pathways. Whether this transfer factor is a protein, a micro-RNA, or an exosome, which again might carry proteins or micro-RNAs, is not clear at this point. The transfer with plasma (our study) seems to exclude cellular elements, and the transfer with dialysate when using a 15-kDa cutoff membrane 13 seems to exclude larger particles and molecules.
Our study now is the first to provide evidence that in both isolated rat hearts and pigs in situ, the myocardial signal transduction of RIPC is identical to that of local ischemic postconditioning. Obviously, there is a point of convergence for signal transduction of various conditioning forms, also upstream of mitochondria. 25 Whether such point of convergence is genuine to the cardiomyocyte or to some other cellular compartment, for example, some sort of resident cell which is activated to release a paracrine factor which then acts on the cardiomyocyte, is unclear at present. Also, an additional involvement of neuronal pathways either during the initiation of the RIPC stimulus, its transfer, or the installation of protection in the pig myocardium cannot be excluded. 45, 46 RIPC, that is, repeated brief cycles of ischemia/reperfusion in a limb or organ remote from the heart, reduces infarct size after coronary artery occlusion/reperfusion. Such remote cardioprotection is also recruitable in humans with acute myocardial infarction or during interventional or surgical coronary revascularization. The protection by RIPC can be transferred with plasma or a plasma dialysate from one individual to another, but the nature of the humoral cardioprotective mediator(s) has not yet been identified. We used a retrograde approach to characterize the cardioprotective humoral RIPC mediator by the signal transduction which it activates in the myocardium. In pigs undergoing RIPC by repeated hindlimb ischemia/reperfusion, infarct size reduction was mediated by activation of signal transducer and activator of transcription 3 in the myocardium. Plasma from pigs undergoing RIPC reduced infarct size in isolated rat hearts by activation of protein kinase B, extracellular signal-regulated kinase, and signal transducer and activator of transcription 3. Apparently, the myocardial signal transduction which is activated by RIPC is species-specific and identical to that of ischemic postconditioning in pigs and rats. 
Supplemental Material
Across-species transfer of protection by remote ischemic preconditioning with species-specific myocardial signal transduction by RISK and SAFE pathways
Expanded Methods
Regional myocardial blood flow in pig myocardium
Regional myocardial blood flow was measured using colored microspheres 1 . In brief, microspheres (2- 
Infarct size (IS) in in-situ pig hearts
At the end of each experiment, the left anterior descending coronary artery was re-occluded, and 5 ml blue dye (Patentblau V, Guerbet GmbH, Sulzbach, Germany) was quickly injected into the left atrium to delineate the area at risk as remaining unstained. The heart was then arrested by electrical induction of fibrillation, removed from the chest and sectioned from base to apex into 5 transverse slices in a plane parallel to the atrioventricular groove. Both sides of each myocardial slice were photographed, and the slice shape and the unstained area at risk were traced manually on transparent film. Slices were then immersed in 0.09 mol/l sodium phosphate buffer containing 1% triphenyl tetrazolium chloride (Sigma-Aldrich Chemie Gmbh, München, Germany) and 8% dextran for 20 min at 37°C to demarcate viable from infarcted tissue. The infarcted triphenyl tetrazolium chloride-negative areas were traced on the same transparent film as the area at risk. The total slice area, the area at risk, and the infarcted area were measured by computer-assisted planimetry. After normalization for the weight of the tissue slices, the size of the area at risk was calculated as fraction of the left ventricle, and the IS was calculated as fraction of the area at risk.
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